Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
ERBB-mutaties als biomarker voor uitkomst plaveiselcelcarcinoom van de long?
jan 2019 | Longoncologie